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Abstract
Background: Interleukin-33 is a member of the IL-1 cytokine family whose functions are mediated and modulated
by the ST2 receptor. IL-33-ST2 expression and interactions have been explored in mouse macrophages but little is
known about the effect of IL-33 on human macrophages. The expression of ST2 transcript and protein levels, and
IL-33-mediated effects on M1 (i.e. classical activation) and M2 (i.e. alternative activation) chemokine marker
expression in human bone marrow-derived macrophages were examined.
Results: Human macrophages constitutively expressed the membrane-associated (i.e. ST2L) and the soluble (i.e.
sST2) ST2 receptors. M2 (IL-4 + IL-13) skewing stimuli markedly increased the expression of ST2L, but neither
polarizing cytokine treatment promoted the release of sST2 from these cells. When added to naïve macrophages
alone, IL-33 directly enhanced the expression of CCL3. In combination with LPS, IL-33 blocked the expression of
the M2 chemokine marker CCL18, but did not alter CCL3 expression in these naive cells. The addition of IL-33 to
M1 macrophages markedly increased the expression of CCL18 above that detected in untreated M1 macrophages.
Similarly, alternatively activated human macrophages treated with IL-33 exhibited enhanced expression of CCL18
and the M2 marker mannose receptor above that detected in M2 macrophages alone.
Conclusions: Together, these data suggest that primary responses to IL-33 in bone marrow derived human
macrophages favors M1 chemokine generation while its addition to polarized human macrophages promotes or
amplifies M2 chemokine expression.
Background
Macrophages play a pivotal role in regulating the initia-
tion, amplification, and resolution of innate immune
responses. Several diseases including atherosclerosis, dia-
betes, cancer, and rheumatoid arthritis are associated
with a defect or alteration in macrophage function [1].
These cells arise in the bone marrow from granulocyte/
macrophage progenitors, which are the precursors of
monocytes. Monocytes exit the bone marrow and in
turn respond to cytokines and chemokines during their
recruitment into tissue where they differentiate into resi-
dent macrophages. Macrophages can be classically acti-
vated (i.e. M1) or alternatively activated (i.e. M2) based
upon the response of these cells to the extracellular
milieu [2]. In the presence of IFN-g and PAMPs such as
LPS, macrophages become M1 activated while in the
presence of Th2-type cytokines such as IL-4 and IL-13,
macrophages undergo alternative activation or are
skewed toward an M2 phenotype [2]. Macrophage
polarization dramatically alters the immune properties
of these cells as evidenced by the potent anti-microbial
properties of M1 macrophages versus the prominent tis-
sue repair properties of M2 macrophages [2]. Although
M1 and M2 markers have been more thoroughly char-
acterized in mouse macrophages [3,4], human macro-
phages show selective soluble and cell membrane
associated marker expression following exposure of
these cells to M1 or M2 skewing conditions [2]. Exam-
ples of chemokines/chemokines receptor markers that
are selectively upregulated under M1 conditions include
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lated under M2 conditions in human macrophages [5].
Mannose receptor is a selective M2 marker in both
mouse [6] and human [5] macrophages.
IL-33, similar to IL-1b and IL-18, is a member the IL-1
family that has a major role in innate immune responses
driven through its receptor ST2 [7-10]. IL-33 is constitu-
tively expressed by endothelial and epithelial cells and is
found associated with chromatin in the nucleus [11]. IL-33
is released by these cells following necrotic cell death,
hence this cytokine has been referred to as an ‘alarmin’
[12,13]. Several experimental models have shown that
binding of recombinant IL-33 to ST2 leads to the induc-
tion of Th2 immune responses [14-16], but its effects on a
number of non-adaptive immune cells have been well
documented [17]. Specifically, a recent study addressed
the effects of IL-33 on mouse macrophages and showed
that this cytokine amplifies the expression of M2 markers
in these cells [18]. Less is known about the immunomodu-
latory effects of IL-33 in human cells but this cytokine is
known to enhance both Th1 and Th2 responses in human
basophils, Th2 cells, iNKT cells, NK cells, mast cells, and
eosinophils [19-22]. However, little is known about the
effect of IL-33 on primary human macrophages.
Herein, we investigated whether human bone marrow-
derived macrophages express ST2 and respond to IL-33,
and whether the activation status of human macro-
phages alters the response by these cells to this cytokine.
These studies showed that human macrophages express
both the transmembrane form of ST2 (ST2L) and the
soluble form of ST2 (sST2). Characterization of the
effect of IL-33 on human macrophage activation sug-
gested that it promoted M1 chemokine generation in
naïve human macrophages but enhanced the expression
of M2 chemokine markers in previously polarized
macrophages, regardless of the prior polarization signals.
Together, these data suggest that IL-33 has a direct
effect on the expression of M1 and M2 chemokine mar-
kers in human macrophages.
Methods
Culture of human bone marrow-derived macrophages
An Institutional Review Board (IRB) at the University
of Michigan Medical School approved the studies
described below (Study Title: The effect of inflamma-
tory disease states on growth, maturation, and gene
expression patterns of bone marrow derived cells;
Study eResearch ID: HUM00005609). Informed con-
sent was not required for IRB approval of this study
because bone marrow was collected at the University
of Michigan Medical Center from patients undergoing
various diagnostic tests and mononuclear cells and
only the unused portions of these bone marrow sam-
ples were studied.
Each bone marrow sample was first subjected to a den-
sity gradient centrifugation over Ficoll-Paque™ Plus (GE
Healthcare Bio-Sciences AB, Uppsala, Sweden) to isolate
cells of myeloid origin. In order to establish a reproduci-
ble protocol for growing macrophages from human bone
marrow, we tested several types of culture conditions,
media, and growth factor combinations. The protocol
that yielded both the greatest number and purity of
macrophages is described herein. Briefly, bone marrow
cells were plated onto 100 mm tissue culture dishes and
5m lo fI s c o v e ’s Modified Dulbecco’sM e d i u m( I M D M ;
Thermo Fisher Scientific Inc., Waltham, MA) supple-
mented with 10% fetal calf serum (FCS), 100 U/ml of
penicillin, 100 μg/ml of streptomycin, b-mercaptoetha-
nol, 25 ng/ml of macrophage colony stimulating factor
(MCSF), 2.5 ng/ml of granulocyte monocyte colony sti-
mulating factor (GMCSF), 50 ng/ml of stem cell factor
(SCF), and 20 ng/ml of IL-3 was added. All cytokine
growth factors were purchased from R&D Systems (Min-
neapolis, MN). Cells received 10 ml of fresh IMDM con-
taining cytokine growth factors at day 3 after plating and
cultured for a total of 7-10 days at 37°C in 10% CO2.
Prior to an experiment, spent media was removed from
the cultured macrophages, the plate was washed with Ca
+2
and Mg
+2 free PBS to remove non-adherent cells, and the
macrophage monolayer was incubated in Ca
+2 and Mg
+2
free PBS for 10 min on ice. Next, macrophages were dis-
lodged via repetitive pipetting. The resultant cell suspension
was centrifuged at 400-× g for 10 min. The cell pellet was
suspended in IMDM containing FCS, 100 U/ml of penicil-
lin, 100 μg/ml of streptomycin, and b-mercaptoethanol and
plated at a density of 1 × 10
6/ml in triplicate wells of a
6-well tissue culture plate.
Flow cytometry of human macrophages
Bone marrow-derived human macrophages were washed
once with buffer containing 0.2% BSA and 0.1% NaN3.
FcR blocking reagent from Miltenyi Biotec was used to
block Fc receptors. These cell suspensions were then
stained with the one of the following antibodies or anti-
body combinations: FITC conjugated CD11b (BD Bios-
ciences, San Jose, CA), PECy7-conjugated CD14
(eBiosciences; San Diego, CA), biotin-conjugated CD163
(BD Biosciences) followed by PECy5 conjugated strepta-
vidin (BD Biosciences), or biotin-conjugated CD68 (BD
Biosciences) followed by PECy5 conjugated streptavidin
(BD Biosciences). Cells were fixed in 4% formalin and
analyzed using Beckman Coulter FC500 and FlowJo
Software (Tree Star Inc.; Ashland, OR).
Effect of IL-33 on M1 and M2 chemokine expression by
human macrophages
In the first series of experiments, macrophages were
p o l a r i z e dt o w a r de i t h e raM 1o rM 2p h e n o t y p eu s i n g
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eration of M1 chemokine markers, triplicate wells (in a
6-well tissue culture plate) containing 2.5 × 10
5 cells
were stimulated with 100 ng/ml of IFN-g (PeproTech;
Rocky Hill, NJ) combined with 1 μg/ml of LPS (Sigma-
Aldrich; St. Louis, MO) for 24 h. To skew macrophages
toward the generation of M2 chemokines, triplicate
wells containing 2.5 × 10
5 cells with the combination of
10 ng/ml of IL-4 and 10 ng/ml of IL-13 (both from
R&D Systems) for 24 h. In other experiments, macro-
phages were incubated with 10 ng/ml IL-33 (IL-33
112-270;
R&D) alone for 24 h. To study the effect of IL-33 on pre-
viously polarized macrophages, macrophages were acti-
vated in M1 or M2 conditions for 24 h. These cells were
washed and exposed to 10 ng/ml of IL-33 alone, IL-33 in
combination with M1 or M2 macrophage skewing cyto-
kines, or the M1 or M2 cytokines alone for an additional
24 h in culture. In all experiments, cell-free supernatants
were removed and individual wells were processed for
immunocytochemistry, protein analysis by Western blot-
ting, or quantitative RNA analysis.
Immunocytochemistry and Western blotting analysis
of ST2
Macrophages were either fixed in 8-well Labtek tissue
culture slides for immunocytochemistry or treated with
protein lysis buffer in 6-well tissue culture plates prior
to Western blotting analysis. Employing a standard
immunocytochemistry technique, an anti-ST2 polyclonal
antibody from ProSci (Poway, CA) was used to stain for
ST2 in primary human macrophages exposed to media
alone, IL-33, M1-polarizing mediators, or M2-polarizing
mediators. IgG control groups were also included in this
protocol. Standard Western blotting techniques were
used to detect ST2L and sST2 in cytoplasmic and
nuclear extracts from cultured naïve and M2-polarized
macrophages.
Quantitative RT-PCR
To analyze gene expression, RNA was extracted from
adherent human macrophages using TriZol (Invitrogen
Life Technologies; Carlsbad, CA). RNA was then con-
verted to cDNA using Murine Moloney Leukemia Virus
reverse transcriptase (Invitrogen Life Technologies). The
resulting cDNA was analyzed by real time q-PCR using
the ABIPRISM 7700 detection system (Applied Biosys-
tems, Foster City, CA). Premixed primer/probe reagents
for CCR7 and CCL3 were purchased from Applied Bio-
systems. The primers used to detect mannose receptor
were ACC TCA CAA GTA TCC ACA CCA TC and
CTT TCATCA CCA CAC AAT CCT C. The primers
used for the detection of CCL18 were TAC CTC CTG
GCA GAT TCC AC and TTA GAA GAG GTG GCC
TCC AG. The following forward and reverse primers
were used for the detection of ST2: (forward) CAG
GAA AGA AAT CGT GTG T, (reverse) GCC AAG
AAC TGA CTG CCT. To further distinguish the solu-
ble form of ST2 (sST2) from the membrane associated
form of this receptor (ST2L) the following primers were
used. Soluble ST2: (forward) AGG CTT TTC TCT TGT
TTC CAG TAA TCG G; (reverse) CAG TGA CAC
AGA GGG AGT TCA TAA AGT TAG A. ST2L: (for-
w a r d )A G GC T TT T CT C TT G TT T CC A GT A A
TCG G; (reverse) GGC CTC AAT CCA GAA CAT
TTT TAG GAT GAT AAC. A SYBR green PCR mix
was used to amplify ST2, ST2L, sST2, mannose recep-
tor, CCL18. The expression of GAPDH was used as
internal control for each PCR reaction.
Statistical Analysis
Analysis of variance (ANOVA) and the Dunnett’st e s t
were used to detect statistical differences between con-
trol and polarized human macrophages with and with-
out IL-33 treatment. P values of ≤ 0.05 were considered
statistically significant.
Results
M1 and M2 chemokine marker expression by human
bone marrow-derived macrophages
Flow cytometric analysis of human bone marrow-
derived macrophages revealed that the culture techni-
ques employed promoted the expression of CD11b,
CD68, and CD163 on approximately 90% of these cells
(Figure 1A). CD14 was also expressed by approximately
40% of the cultured macrophages. Cultures of human
macrophages were skewed toward a M1 phenotype
upon exposure to IFN-g and LPS for 24 h (Figure 1B).
This was apparent by the elevated transcript levels of
the M1 markers CCR7 and CCL3 in these cells (Figure
1B). The fold-increase in CCL3 transcript levels in M1
macrophages reached statistical significance compared
with untreated or control macrophages (Figure 1B).
Conversely, transcripts for two human M2 markers
CCL18 and mannose receptor [5], but not the M1 mar-
kers CCR7 or CCL3 [5], were significantly elevated
under M2 conditions compared with control macro-
phages (Figure 1C). Thus, with the appropriate external
stimuli, human macrophages appeared to predominately
express either M1 or M2 chemokine markers.
ST2 expression by human macrophages exposed to either
M1 or M2 conditions
Transcript and protein expression of ST2 was next
determined in naïve, M1- and M2-polarized human
macrophages. Quantitative PCR revealed that ST2 was
constitutively expressed by macrophages but the expo-
sure of these cells either to M1 (Figure 2A) or M2 (Fig-
ure 2B) conditions markedly increased the expression of
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increase in ST2 expression was restricted to the mem-
brane form of this receptor, namely ST2L and increases
in soluble ST2 transcript levels were not apparent with
either M1 or M2 conditions (Figure 2A &2B).
Immunocytochemical and Western blotting analysis of
ST2L and sST2 protein expression in human macro-
phages are summarized in Figure 3. ST2L protein was
present in naïve macrophages (Figure 3E), and in cul-
tures of human macrophages exposed to IL-33 alone
(Figure 3F), and when cultured in M1 conditions (Figure
3G) and M2 conditions (Figure 3H). Because the inten-
sity of ST2L staining appeared to be greatest in M2-
treated macrophages, Western blotting analysis was
completed to compare expression in these macrophages
with naïve or control macrophages. As shown in Figure
3I &3J, both ST2L and sST2 were increased in expres-
sion in M2 macrophages compared with the control (i.e.
medium alone) group. Together these data showed that
ST2 protein was present in human macrophages
exposed to either M1 or M2 conditions, suggesting that
both types of macrophages might be responsive to exo-
genous IL-33.
Exogenous IL-33 blocked LPS-mediated induction of a M2
but not an M1 chemokine marker expression in human
macrophages
ST2 has been shown to sequester MyD88 (an adaptor
molecule necessary for PAMP activation of cells) away
from TLR4 thereby blunting LPS-induced activation of
mouse macrophages [23]. To address whether ST2 acti-
vation similarly altered LPS responses in human macro-
phages, we next examined whether the addition of IL-33
to naïve human macrophages modulated LPS activation
in these cells. CCL18 (Figure 4A) and CCL3 (Figure 4B)
were selected as the prototypic M2 and M1 chemokine
markers, respectively. IL-33 failed to markedly modulate
IL-1b-, IL-6-, Pam3Cys-, or PolyI:C-induced expression
Figure 1 M1 and M2 polarizing conditions in cultured human bone marrow-derived macrophages promote the expression of either
M1- or M2-specific transcripts, respectively.( A) Representative flow cytometric analysis of primary human macrophages derived from bone
marrow. Cells were stained using anti-CD11b, anti-CD14, anti-CD163, or anti-CD68 antibodies. (B) Human macrophages stimulated with IFN-g
+LPS (i.e. M1 condition) or (C) IL-4+IL-13 (i.e. M2 condition) and gene expression was analyzed 24 h later by TAQMAN. Transcript levels for each
M1 and M2 factor are expressed as fold increase over transcript levels of these factors in human macrophages exposed to media alone (i.e.
control condition). Each symbol represents a single donor and macrophages from 5 to 8 bone marrow donors were analyzed; mean and SEM
are also shown in panels B and C.* P≤ 0.05 compared with transcript levels in control macrophages; **P ≤ 0.01 compared with transcript levels
in control macrophages.
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expression of this chemokine( F i g u r e4 A ) .C o n v e r s e l y ,
the addition of IL-33 to naïve macrophages did not
block the ability of LPS to drive the transcript expres-
sion of CCL3 (Figure 4B). Thus, the inhibitory effect of
IL-33 on LPS activation appeared to be restricted to a
M2 but not a M1 chemokine marker in naïve human
macrophages.
Effect of IL-33 on macrophage M1 and M2 chemokine
expression
Because IL-33 had a differential effect on the expression
of M1 and M2 chemokine markers in naïve macro-
phages, additional experiments were undertaken to
explore this novel modulatory effects of IL-33 on
human macrophages. As shown in Figure 5A, the addi-
tion of IL-33 alone to naïve macrophages significantly
decreased the transcript expression of CCL18, while it
significantly enhanced the transcript levels of CCL3
compared with transcript levels of these chemokines in
untreated, naïve macrophages. When IL-33 was added
with M1 polarizing mediators to macrophages, the tran-
script expression in these cells was dramatically shifted
toward CCL18 expression; transcript levels of this
chemokine were significantly increased approximately
30-fold above the M1 condition alone (i.e. control con-
dition for this study) (Figure 5B). The addition of IL-33
to the M1 condition only modestly increased CCL3
transcript levels in these cultures. The addition of IL-33
with M2 polarizing mediators to human macrophages
did not appear to skew these cells appreciably toward
either CCL18 or CCL3 transcript expression since both
chemokines were similarly increased above the M2 con-
dition alone approximately 2-4 fold (Figure 5C). Thus,
the addition of IL-33 to naïve macrophages favored the
expression of an M1-associated chemokine marker over
an M2-associated chemokine marker, but its addition to
human macrophages cultured in M1 conditions pro-
moted the expression of the M2 marker CCL18.
Effect of IL-33 on human macrophages previously
exposed to either M1 or M2 conditions
To investigate the effect of IL-33 on human macro-
phages following their exposure for 24 h to either M1
or M2 polarizing conditions, IL-33 alone, IL-33 with M1
or M2 polarizing mediators, or M1 or M2 polarizing
mediators alone were added for an additional 24 h to
primary human macrophage cultures. As shown in Fig-
ure 6A, the addition of IL-33 alone macrophages
exposed to M1 mediators did not induce the expression
of CCR7 to the same magnitude as that observed in M1
polarized cultures exposed to M1 mediators with IL-33
or M1 mediators. Similar results were observed with
CCL3 transcript expression although IL-33 alone did
Figure 2 ST2, membrane bound (ST2L), and soluble (s) ST2
transcript levels in M1 and M2 polarized human bone marrow-
derived macrophages.( A) Transcript levels of ST2, ST2L, and sST2
from macrophages exposed to M1 polarizing mediators. (B)
Transcript levels of ST2, ST2L, and sST2 from macrophages exposed
to M2 polarizing mediators. Results are expressed as fold increase in
transcript levels compared with levels of these transcripts in human
macrophages exposed to media alone (i.e. control condition). Each
symbol denotes a single donor (n = 5-14 donors); mean and SEM
are also shown.
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human macrophages (Figure 6A). However, the presence
of IL-33 with M1 polarizing mediators significantly
increased the expression of the M2 marker CCL18 in
macrophages compared with M1 macrophages alone
(Figure 6A). In cultures of M2 polarized macrophages,
transcript levels of CCL18 were markedly induced after
the secondary addition of IL-33 alone or IL-33 with M2
mediators for an additional 24 h (Figure 6B). Interest-
ingly, the secondary addition of M2 mediators did not
f u r t h e re n h a n c eC C L 1 8e x p r e s s i o ni nM 2p o l a r i z e d
macrophages (Figure 6B). The effect of IL-33 on man-
nose receptor transcript expression was also examined
and similar results were observed; the secondary
addition of the combination of IL-33 and M2 mediators
further enhanced mannose receptor expression on M2
polarized macrophages. Overall, these data suggest that
IL-33 appears to promote M2 chemokine expression in
polarized macrophages since it promoted CCL18 in M1
human macrophages and appears to further enhance the
expression of M2 markers in M2-polarized
macrophages.
Discussion
The present study demonstrates that human macrophages
express ST2 and respond to the presence of IL-33. The
expression of ST2, particularly the transmembrane form
of this receptor, and to a lesser extent the soluble version
Figure 3 ST2 protein expression in human bone marrow-derived macrophages.( A-H) Immunostaining of human macrophages cultured
on Lab-Tek slides after exposure to medium alone (A & E), IL-33 (B & F), M1 polarizing mediators (C & G), or M2 polarizing mediators (D & H).
IgG controls are shown in panels A, B, C, & D. (I) Western blotting for ST2L and sST2 protein was performed in protein extracts from naïve and
M2-polarized human macrophages; CE = cytoplasmic extract and NE = nuclear extract. (J) Quantitative analysis of ST2L and sST2 protein band
intensity.
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macrophages either toward the expression of either M1 or
M2 chemokine markers. Macrophages also showed differ-
ential responses to IL-33, which appeared to depend on
the activation status of these cells. Naïve macrophages
responded to IL-33 through the elaboration of M1 chemo-
kine markers. Conversely, when added to M1 or M2 polar-
izing or polarized conditions, this IL-1 like cytokine
promoted the expression of M2 chemokine markers in
human macrophages. Together these findings suggest that
there is a dynamic range of human macrophage responses
to IL-33.
The ST2 gene encodes for two distinct isoforms: ST2L
and sST2. ST2L is the transmembrane form of ST2 and
is the active IL-33-signaling receptor while the soluble
Figure 4 Regulatory effects of IL-33 in LPS-activated human
macrophages.( A) CCL18 transcript levels in primary macrophages
exposed to cytokine or TLR ligand alone or in combination with 10
ng/ml of IL-33. (B) CCL3 transcript levels in primary macrophages
exposed to cytokine or TLR ligand alone or in combination with 10
ng/ml of IL-33. Results are expressed as fold increase in transcript
levels compared with levels of these transcripts in human
macrophages exposed to media alone (i.e. control condition). Data
are expressed as mean ± SEM and are representative of
experiments performed with 4 donor macrophage lines.
Figure 5 Effect of IL-33 on human macrophage polarization.( A)
CCL18 and CCL3 transcript expression in macrophages following
exposure to IL-33 (10 ng/ml) alone for 24 h. (B) CCL18 and CCL3
transcript expression in human macrophages following exposure to
M1 polarizing mediators + IL-33 (10 ng/ml) for 24 h. (C) CCL18 and
CCL3 transcript expression in human macrophages following
exposure to M2 polarizing mediators + IL-33 (10 ng/ml) for 24 h.
Results are expressed as fold increase in transcript levels compared
with levels of these transcripts in human macrophages exposed to
media alone (i.e. control condition). Data are shown as mean ± SEM
and are representative of three separate experiments with 3 donor
macrophage lines. *P ≤ 0.05 compared with transcript levels in
appropriate control macrophages.
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decoy for IL-33. Both ST2 isoforms are expressed by a
number of innate and adaptive immune cells and their
expression is altered by cytokine signals (including IL-33
itself) in both types of immune cells [17]. Regarding
mouse macrophages, both forms of ST2 have been
described in these cells although we have previously
observed that ST2L levels are higher in alternatively
activated or M2 mouse macrophages [24]. These data
are consistent with the observation that exogenous IL-
33 amplifies the polarization of alternatively activated
macrophages [25]. In the present study, both ST2L and
sST2 transcript and protein expression were examined
in human macrophages. Both forms of ST2 were present
in naïve human macrophagesa l t h o u g hs S T 2w a sn e v e r
detected in the cell-free supernatants from these cul-
tures (data not shown). Both M1 and M2 polarizing
mediators promoted the transcript expression of ST2L
but not sST2 whereas the M2 polarizing conditions
increased protein expression for both forms of ST2.
These data are consistent with previous mouse macro-
phage data and highlight that ST2 expression is promi-
nent on human M2 macrophages, but it is also
expressed by naïve and M1 macrophages as well.
In contrast to earlier findings that functional IL-33
was a product of caspase-1 cleavage [9], it is now estab-
lished that this cytokine is active without proteolysis
and is inactivated by apoptotic caspases [8-10,26]. Full
length IL-33 (IL-33
1-270) is released from necrotic cells
[8] or by activated mouse macrophages [27] indepen-
dent of caspase or calpain activity. A truncated version
of IL-33 (IL-33
112-270) is formed via the activity of cas-
pase 1 but it appears to lack the full potency of full
length IL-33 [10]. At the time these studies were under-
taken, recombinant commercial sources of IL-33 were
limited to IL-33
112-270 thus this was the form of IL-33
used in cultures of human macrophages. Key observa-
tions from the present study included the M1 skewing
effect of recombinant IL-33 on naïve human macro-
phages as evidenced by enhanced CCL3 expression. The
inhibitory effect of IL-33 on LPS-induced CCL18
expression was consistent with the documented inhibi-
tory effect of ST2 activation on TLR4 signaling [23,28].
However, IL-33 had no inhibitory effect on the expres-
sion of CCL3 by naïve human macrophages, data that
was consistent with studies in mouse macrophages indi-
cating that IL-33 did not inhibit LPS activation of these
cells [18]. Thus, the addition of recombinant IL-33 to
naïve human macrophages appeared to skew these cells
toward the expression of M1 chemokine markers.
When added to macrophage cultures containing polar-
izing or polarized conditions, it was apparent that IL-33
h a dad i v e r g e n te f f e c tf r o mt h a to b s e r v e di nc u l t u r e so f
naïve human macrophages. Specifically, IL-33 promoted
or amplified M2-associated markers such as CCL18 and
mannose receptors in these cells. These data are consis-
t e n tw i t hap r e v i o u s l yp u b l i shed study showing that IL-
33 amplifies the polarization of alternatively activated or
M2 mouse macrophages [25] and contributes to Th2
responses [14,29]. At present, an explanation of the M2
skewing properties of IL-33 in polarizing or polarized
human macrophages is not clear, but further studies will
be directed at exploring the role of CCL18 in this pro-
cess. CCL18 has no known mouse homolog and it has
been described as a potent inducer of alternative activa-
tion in human macrophages thereby promoting fibrotic
Figure 6 Effect of IL-33 on human macrophages previously
exposed to either M1 or M2 conditions. M1- (i.e. CCR7 and CCL3)
and M2- (i.e. CCL18 and mannose receptor) associated markers in
human macrophages previously exposed to M1 (A)o rM 2( B)
conditions for 24 h, which were secondarily challenged with IL-33
alone (10 ng/ml), IL-33 + M1 or M2 polarizing mediators, or M1 or
M2 polarizing mediators for an additional 24 h. Results are
expressed as fold increase in transcript levels compared with levels
of these transcripts in human macrophages exposed to media alone
(i.e. control condition). Data shown are mean ± SEM, and these data
are representative of three separate experiments with 3 donor
macrophage lines. **P ≤ 0.01 compared with transcript levels in
appropriate control macrophages.
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moted the expression of M2 chemokine markers in
macrophages previously exposed to M1 or M2
conditions.
Conclusions
this study addressed the effect of IL-33 on the activation
and polarization of primary human macrophages. These
findings point to a dual effect of IL-33 that depends on
the activation status of these cells, findings that are con-
sistent with those of Smithgall and colleagues [20] who
demonstrated that IL-33 amplified both Th1 and Th2
type responses in human immune cells. Thus, the pre-
sent findings highlight the complex immunomodulatory
role of this cytokine on human macrophages.
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